|
Acornex is a pharmaceutical venture company dedicated to the discovery, development, and commercialization of drugs to treat brain diseases such as brain cancers and neurodegenerative diseases by utilizing novel molecular transporters which are uniquely capable of crossing the blood-brain barrier. Acornex is also focusing on the development of novel molecular transporters that can target
|
|
|
intracellular-organelles such as mitochondria and nucleus. The latter platform technology will enable successful delivery of apoptosis inhibitors, and genes and siRNAs for the treatment of cancers and genetic diseases. Acornex aims to develop and commercialize primarily through academic collaborations and corporate partnerships, pharmaceutical products with highly improved brain and
specific organelle bioavailability based on the proprietary molecular carrier technology.
The initial marketable substances include 'delivery-enhanced' pharmaceutical products based on currently available drugs or drug candidates that have good in vitro activity but display poor bioavailability (ADME properties) for important indications at desired organs and tissues such as brain (target site for CNS agents), organelles such as nucleus (target for gene therapy) and mitochondria (target for mitochondrial diseases such as Huntington's, Lou Gehrig's and Alzheimer's). As such drug cargoes are presumed
to have well-documented efficacy and safety profiles, and Acornex plans to work together with the producing/marketing corporate partners to develop and commercialize the enhanced version of the drugs as either new NCE (prodrug form) or as new formulation.
Acornex was founded in 2004 as a privately-held pharmaceutical venture company by Professor Sung-Kee Chung, a highly accomplished bioorganic and medicinal chemist in the US as well as in Korea. Acornex main office is located in the Maryland's I-270 technology corridor, a location that is capable of providing an opportunity for collaboration with the National Institutes of Health (NIH) and ready accessibility to the Food and Drug Administration (FDA). The platform technologies and product candidates for various intractable
brain diseases under development are the results of research being carried out primarily in Dr. Chung's laboratories at Pohang University of Science & Technology in Korea in collaboration with many researchers around the world.
|
